Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia

Pharmacogenomics

Volumn 9, Issue 2, 2008, Pages 157-167

  Fijal, Bonnie ^a   Ricci, Deborah ^a   Vercammen, Els ^b   Palmer, Peter A ^c   Fotiou, Fotis ^d   Fife, Daniel ^a   Lindholm, Anders ^d   Broderick, Erin ^a   Francke, Stephan ^a   Wu, Xiaodong ^a   Colaianne, James ^a   Cohen, Nadine ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Johnson and Johnson Pharmaceutical Services   (United States)

Author keywords

Ab positive PRCA; Anemia; Eprex ; Erythropoetin; Immunogenicity; Pharmacogenomics; Recombinant protein

Indexed keywords

ERYTHROPOIETIN ANTIBODY; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; HLA DR5 ANTIGEN; RECOMBINANT ERYTHROPOIETIN; AUTOANTIBODY; ERYTHROPOIETIN; HLA DQ ANTIGEN; HLA-DRB1 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTIBODY PRODUCTION; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; EXPLORATORY RESEARCH; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INCIDENCE; MALE; PHARMACOGENOMICS; PURE RED CELL ANEMIA; ALLELE; CASE CONTROL STUDY; GENETICS; IMMUNOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; RISK;

ADULT; AGED; ALLELES; AUTOANTIBODIES; CASE-CONTROL STUDIES; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GENE FREQUENCY; GENOTYPE; HLA ANTIGENS; HLA-C ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RED-CELL APLASIA, PURE; RETROSPECTIVE STUDIES;

EID: 42449091557     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.2.157     Document Type: Article

References (37)

1. Bergrem H, Danielson BG, Eckardt KU, Kurtz A, Stridsberg M: A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Erythropoietin: Molecular Physiology and Clinical Application. Marcel Dekker, NY, USA, 266-275 (1993).
2. Pece R, de la Torre M, Alcazar R, Urra JM: Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N. Engl. J. Med. 335, 523-524 (1996).
3. Prabhakar S, Muhlfelder T: Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin. Nephrol. 47, 331-335 (1997).
4. Casadevall N, Nataf J, Viron B et al.: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 469-475 (2002).
5. Cournoyer D, Toffelmire E, Wells G et al.: Antierythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risks. J. Am. Soc. Nephrol. 15, 2728-2734 (2004).
6. Bennett C, Luminari S, Nissenson A et al.: Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. 351, 1403-1408 (2004).
7. Schellekens H: Immunologic mechanisms of FPO-associated pure red cell aplasia. Baillieres Best Pract. Res. Clin. Haematol. 18, 473-480 (2005).
8. Rossert J, Casadevall N, Eckardt K-U: Anti-erythropoietin antibodies and pure red cell aplasia. J. Am. Soc. Nephrol. 15, 398-406 (2004).
9. Casadevall N: What is antibody-mediated pure red cell aplasia (Ab-positive PRCA)? Nephrol. Dial. Transplant. 20(Suppl. 4), iv3-iv8 (2005).
10. Casadevall N, Cournoyer D, Marsh J et al.: Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur. J. Haematol. 73, 389-396 (2004).
11. Bennett C, Cournoyer D, Carson K et al.: Long-term outcome of individuals with pure red cell-aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from research on adverse drug events and reports (RADAR) project. Blood 106, 3343-3347 (2005).
12. Sharma B, Bader F, Templeman T, Lisi P, Ryan M, Heavner GA: Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with EPREX®. EJHP5, 86-91 (2004).
13. Boven K, Stryker S, Knight J et al.: The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 67, 2346-2353 (2005).
14. Ryan MH, Heavner GA, Brigham-Burke M, et al.: An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int. Immunopharmacology 6, 647-655 (2006).
15. Porter S: Human immune response to recombinant proteins. J. Pharma. Sci. 90, 1-11 (2001).
16. Macdougall IC: Antibody-mediated pure red cell aplasia (Ab-positive PRCA): epidemiology, immunogenicity and risks. Nephrol. Dial. Transplant. 20(Suppl. 4), iv9-iv15 (2005).
17. Praditpornsilpa K, Buranasot S, Bhokaisuwan N et al.: Recovery from anti-recombinant-human-erythropoietin associated pure red cell aplasia in end-stage renal disease patients after renal transplantation. Nephrol. Dial. Transplant. 20, 626-630 (2005).
18. Praditpornsilpa K, Kupatawintu P, Mongkonsritragoon W: The association of anti-r-HuEPO associated pure red cell aplasia with HLA-DRB1*9 and HLA-DRB1*12. Anaemia in CKD and dialysis. Abstract presented at the EDTA Congress, Barcelona, Spain, June 21-24, 2007. Nephrol. Dial. Transplant. 22 (Suppl. 6), v1344 (2007).
19. Middleton D, Menchaca L, Rood H, Komerofsky R: www.allelefrequencies.net new allele frequency database. Tissue Antigens 61, 403-407 (2003).
20. Chan S, Tan T: HLA and allopurinol drug eruption. Dermatologica 179, 32-22 (1989).
21. Shiraoki S, Kagaya F, Suzuki Y, Joukou S: Stevens-Johnson syndrome induce 1 by methazolamide treatment. Arch. Ophthalmol. 115, 550-553 (1997).
22. Mallal S, Nolan D, Witt M et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
23. Hetherington S, Hughes A, Mosteller M et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
24. Hughes D, Javier V, Ward C, Alfirevic A, Park K, Pirmohamed M: Cost-effectiveness analysis of HLA-B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14, 335-342 (2004).
25. Martin A, Nolan D, Gauieri S et al.: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101, 4180-4184 (2004).
26. Hung S, Chung W, Liou L et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102, 4134-4139 (2005).
27. Pirmohamed M: Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J. 8, E20-E26 (2006).
28. Tracey R, Greway A, Smiell J et al.: The detection of anti-erythropoietin antibodies in human serum and plasma, Part I. validation of the protocol for a radioimmunoprecipitation assay. J. Immunol. Methods 283, 317-329 (2003).
29. 3H-thymidine uptake assay for neutralizing antibodies. J. Immunol. Methods 300, 179-191 (2005).
30. Bugawan TL, Erlich HA: Rapid typing of HLA-DQB1 DNA polymorphism using nonradioactive oligonucleotide probes and amplified DNA. Immunogenetics 33, 163-170 (1991).
31. Scharf S, Griffith R, Erlich H: Rapid typing of DNA sequence polymorphisms at the HLA-DRB1 locus using the polymerase chain reaction and nonradioactive oligonucleotide probes. Hum. Immunol. 30, 190-201 (1991).
32. Yunis I, Salazar M, Yunis E: HLA-DR generic typing by AFLP. Tissue Antigens 46, 258-280 (1991).
33. Shaffer A, Falk-Wade J, Tortorelli V: HLA-DRw52 associated DPB1 alleles: identification using polymerase chain reaction-amplified DNA, sequence-specific oligonucleotide probes, and a chemiluminescent detection system. Tissue Antigens 39, 84-90 (1992).
34. Kimura A, Dong R, Harada H, Sasazuki T: DNA typing of HLA class II genes in B-lymphoblastoid cell lines homozygous for HLA. Tissue Antigens 40, 5-12 (1992).
35. Maiers M, Hurley C, Perlee L et al.: Maintaining updated DNA-based HLA assignments in the National Marrow Donor Program bone marrow registry. Rev. Immunog. 2, 449-460 (2001).
36. Chung W, Hung S, Chen Y: Human leukocyte antigens and drug hypersensitivity. Curr. Opin. Allergy Clin. Immunol. 7, 317-323 (2007).
37. Knipper AJ, Hakenberg P, Enczmann et al.: HLA-DRB1,3,4,5 and -DQB1 allele frequencies and HLA-DR/DQ linkage disequilibrium of 231 German caucasoid patients and their corresponding 821 potential unrelated stem cell transplants. Hum. Immunol. 61, 605-614 (2000).